九強生物(300406.SZ)業績快報:2020年淨利降66.20%至1.12億元
格隆匯 3 月 25日丨九強生物(300406.SZ)披露2020年度業績快報,2020年實現營業收入8.48億元,同比增長0.86%;營業利潤為1.54億元,同比下降59.32%;利潤總額為1.38億元,同比下降63.98%;歸屬於母公司普通股東的淨利潤為1.12億元,同比下降66.20%;基本每股收益0.21元。
報吿期內,由於全國各地受國外疫情輸入和本土疫情反彈的影響,醫療機構正常的診療工作受到一定限制,生化診斷試劑終端需求受到一定影響,疫情期間,公司原材料採購、生產安排、物流配送受到一定程度限制,生產經營受到一定的影響。與此同時公司不斷加大市場開拓力度,拓展銷售渠道,尋求新的經濟增長點。同時,以市場為導向,進一步加大研發投入,不斷創新產品,豐富產品結構。
公司合併範圍本期較上期增加福州邁新生物技術開發有限公司及其孫公司、福州戴諾斯醫學科技有限公司、福州邁新醫學檢驗所有限公司、Lumatas BioSystems Inc.
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.